Acella Pharmaceuticals and Neuvosyn Laboratories have announced positive topline results from a phase 2 clinical trial of ...

Xeltis has announced successful results from its aXess EU phase 3 trial, confirming the potential of its restorative vascular ...

Three new studies have launched in Manchester to evaluate the effectiveness of vaccines for severe acute respiratory ...

Tezspire (tezepelumab) has received a positive opinion from the CHMP for the treatment of chronic rhinosinusitis with nasal ...

BlueRock Therapeutics has dosed the first patient in its pivotal phase 3 trial of bemdaneprocel, an investigational cell ...

Johnson & Johnson has announced a positive opinion from the CHMP recommending expanded marketing authorisation for TREMFYA ...

Nxera Pharma and Cancer Research UK have announced the first patient has been dosed in a phase 2a trial of HTL0039732, an ...

The European Commission has approved ROMVIMZA (vimseltinib) for adult patients with symptomatic tenosynovial giant cell ...

AstraZeneca’s Imfinzi (durvalumab) has been approved for NHS use in England and Wales for adults with limited-stage small ...

The MHRA has approved vorasidenib (Voranigo) for patients aged 12 and above with grade 2 astrocytoma or oligodendroglioma ...

Among patients with HS, HiSCR75, HiSCR90 and HiSCR100 responses seen at one year were sustained and improved to three years ...

Modus Therapeutics will present new research on sevuparin for chronic kidney disease (CKD) with anemia at the 32nd Symposium ...